KRAS mutations are the most common genetic abnormalities in cancer, but the distribution
of specific mutations across cancers and the differential responses of patients with specific …

KRAS is the most commonly mutated oncogene in human cancer. Most KRAS-mutant
cancers depend on sustained expression and signaling of KRAS, thus making it a high …

Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver
events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly …

KRAS is the most frequently mutated oncogene in cancer, yet there is little understanding of
how specific KRAS amino acid changes affect tumor initiation, progression, or therapy …

The three mammalian RAS genes (HRAS, NRAS and KRAS) encode four proteins that play
central roles in cancer biology. Among them, KRAS is mutated more frequently in human …

RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS is the most
frequently mutated followed by NRAS. The emblematic KRAS mutant cancers are …

Mutations in the KRAS oncogene represent one of the most prevalent genetic alterations in
colorectal cancer (CRC), the third leading cause of cancer-related death in the US. In …

Mutational activation of KRAS is a common oncogenic event in lung cancer and other
epithelial cancer types. Efforts to develop therapies that counteract the oncogenic effects of …

KRAS mutations are among the most common genetic alterations in lung, colorectal, and
pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit …

RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …